Search results for "Placental growth factor"

showing 4 items of 4 documents

TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy.

2020

Transforming growth factor &beta

0301 basic medicinePlacental growth factorMaleVascular Endothelial Growth Factor Aserum biomarkersGastroenterologylcsh:ChemistryPathogenesischemistry.chemical_compound0302 clinical medicineTransforming Growth Factor betaMedicineMolecular Targeted Therapylcsh:QH301-705.5SpectroscopyAfliberceptAged 80 and overGeneral MedicineDiabetic retinopathyTGFComputer Science ApplicationsVascular endothelial growth factor ABiomarker (medicine)Intercellular Signaling Peptides and ProteinsFemaleTomography Optical Coherencemedicine.drugmedicine.medical_specialtyanti-VEGFAAnti-VEGFA; Diabetic retinopathy; Serum biomarkers; TGFCatalysisArticleProinflammatory cytokineInorganic Chemistry03 medical and health sciencesTGFβInternal medicineHumansPhysical and Theoretical ChemistryMolecular BiologyAgedDiabetic Retinopathybusiness.industryOrganic Chemistrymedicine.diseaseeye diseases030104 developmental biologylcsh:Biology (General)lcsh:QD1-999chemistryDiabetes Mellitus Type 2ROC Curve030221 ophthalmology & optometryGlycated hemoglobinbusinessBiomarkersInternational journal of molecular sciences
researchProduct

Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease.

2015

Background: Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1. Methods: The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported. Results: In Kaplan–Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0…

0301 basic medicinePlacental growth factorMalemedicine.medical_specialtyClinical BiochemistryCoronary Artery DiseaseKaplan-Meier Estimate030204 cardiovascular system & hematologyPregnancy ProteinsCoronary artery disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoveryNatriuretic Peptide BrainmedicineHumansMyocardial infarctionPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Proportional hazards modelbusiness.industryBiochemistry (medical)Hazard ratioMiddle Agedmedicine.diseasePrognosisPeptide FragmentsVascular endothelial growth factor030104 developmental biologyEndocrinologychemistryCohortCardiologyFemalebusinessSoluble fms-like tyrosine kinase-1Follow-Up StudiesBiomarkers in medicine
researchProduct

Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsi…

2013

Background: Aim of the study was a critical assessment of the clinical validity of the prenatal determination of sFlt-1/PlGF for preeclampsia (PE), pregnancy-induced hypertension (PIH), and proteinuria. Our analysis was based on a specificity of 95 % and a sensitivity of 82 % for the prediction of preeclampsia, as described by Elecsys (Roche). Methods: In this retrospective study the ratio of the prenatal antiangiogenic factor sFlt-1 (soluble fms-like tyrosine kinase-1) to the proangiogenic factor PIGF (placental growth factor) was analyzed using the electrochemiluminescence immunoassay of Elecsys (Roche Diagnostics, Mannheim, Germany) in 173 pregnant women. Sixty-three women with PE, 34 wo…

Placental growth factorGynecologymedicine.medical_specialtyProteinuriabusiness.industryObstetrics and GynecologyIntrauterine growth restrictionmedicine.diseaseGastroenterologyArticlePreeclampsiaBlood pressurePIGFInternal medicineMaternity and Midwiferyembryonic structuresmedicineGestationmedicine.symptombusinessSoluble fms-like tyrosine kinase-1
researchProduct

Imbalance of expression of bFGF and PK1 is associated with defective maturation and antenatal placental insufficiency.

2013

Abstract Objective Defective placental maturation is associated with restricted functional capacity and adverse perinatal fetal outcomes. The aim of the study was a comparative analysis of the role of mRNA expression of various angiogenic factors in placental maturation defects. Study design We examined the mRNA expression patterns of prokineticin 1 (PK1), its receptors (PKRs), basic-fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in tissue from third-trimester placentae that exhibited delayed or accelerated villous maturation. Results The expression of PK1 and PKR2 was elevated in placental tissue exhibiting accelerated maturati…

Placental growth factorVascular Endothelial Growth Factor Amedicine.medical_specialtyPlacenta DiseasesReceptors Peptidemedicine.medical_treatmentPlacentaPregnancy Trimester ThirdPlacental insufficiencyBiologyPregnancy ProteinsReceptors G-Protein-CoupledGastrointestinal Hormoneschemistry.chemical_compoundPregnancyInternal medicinemedicineHumansReceptorPlacenta Growth FactorFetusGrowth factorObstetrics and Gynecologymedicine.diseaseProkineticinVascular endothelial growth factorEndocrinologyReproductive MedicinechemistryPIGFFemaleFibroblast Growth Factor 2Vascular Endothelial Growth Factor Endocrine-Gland-DerivedEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct